Ultrasound-enhanced Pt-coordinated polymer immunopotentiators and heterogenic fusion membrane-based multifunctional tumor vaccine nanoplatforms for melanoma treatment.

ABSTRACT: A tumor cell membrane (CM)-based biomimetic membrane tumor vaccine is an emerging prevention and treatment strategy in tumor immunotherapy. However, a single CM mostly has a weak immune-boosting effect. Here, a heterogenic fusion membrane tumor vaccine, EV-CM, was successfully constructed by fusing extracellular vesicles (EVs) from S. aureus and CM from B16F10 melanoma cells. Inheriting the advantages of parental components, the EV-CM combines tumor antigens with natural adjuvants that can be used for immunotherapy and can be easily synergistic with complementary therapies. In vivo vaccine tests have shown that EV-CM can activate immune antitumor responses and prevent tumorigenesis. To further enhance the immunotherapeutic and antimetastatic effects of EV-CM, Pt-porphyrin coordination poly

SUBMITTER: Guo R 

PROVIDER: S-EPMC12379254 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature